Multiple myeloma -a heterogeneous challenge

about 10% of hematological malignancies is multiple myeloma. despite relatively low incidence , ecomonic impact is high.we surely cannot treat all patients in the same way.risk stratification is mandatory and it will be influence on prognosis,clinical trial selection and therapy.with the availability of novel therapies, new markers are now more important than ever in predicting not only risk and outcome but also treatment selection.here is a short review of this heterogeneous disease and usage of personalized medicine for risk stratification and treatment modality.